308 related articles for article (PubMed ID: 23742030)
1. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.
Krause K; Spohr A; Zuberbier T; Church MK; Maurer M
Allergy; 2013 Jul; 68(7):921-8. PubMed ID: 23742030
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
4. Bilastine: a new H
Church MK; Labeaga L
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
[TBL] [Abstract][Full Text] [Related]
5. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.
Church MK
Inflamm Res; 2011 Dec; 60(12):1107-12. PubMed ID: 21874559
[TBL] [Abstract][Full Text] [Related]
6. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
Yagami A; Furue M; Togawa M; Saito A; Hide M
J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
[TBL] [Abstract][Full Text] [Related]
7. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study.
Siebenhaar F; Degener F; Zuberbier T; Martus P; Maurer M
J Allergy Clin Immunol; 2009 Mar; 123(3):672-9. PubMed ID: 19201016
[TBL] [Abstract][Full Text] [Related]
8. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
Wolthers OD
Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
[TBL] [Abstract][Full Text] [Related]
13. How bilastine is used to treat allergic rhinitis and urticaria in children.
Rodríguez Del Río P; Rodríguez Fernández F; Ballester Asensio E; Tortajada-Girbés M
Immunotherapy; 2022 Jan; 14(1):77-89. PubMed ID: 34850647
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
Togawa M; Yamaya H; Rodríguez M; Nagashima H
Clin Drug Investig; 2016 Dec; 36(12):1011-1021. PubMed ID: 27498100
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
Sastre J; Mullol J; Valero A; Valiente R;
Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
[TBL] [Abstract][Full Text] [Related]
17. Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.
Abajian M; Curto-Barredo L; Krause K; Santamaria E; Izquierdo I; Church MK; Maurer M; Giménez-Arnau A
Acta Derm Venereol; 2016 Jan; 96(1):56-9. PubMed ID: 26038847
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
Church MK
Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers.
Antonijoan R; Coimbra J; García-Gea C; Puntes M; Gich I; Campo C; Valiente R; Labeaga L
Curr Med Res Opin; 2017 Jan; 33(1):129-136. PubMed ID: 27659218
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of bilastine: 2nd generation H1-antihistamines.
Scaglione F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
